© 2025 HSP News Service, L.L.C.
In a 10-year update of a Chinese phase III trial (SYSUCC-001) reported in The Lancet Oncology, Yuan et al found that the sequential addition of metronomic capecitabine to standard adjuvant therapy continued to be associated with significant benefits in patients who had undergone surgery for early...
In a pooled analysis of randomized neoadjuvant trials reported in The Lancet Oncology, Conforti et al found that distant disease–free survival was a “robust” surrogate endpoint for overall survival in many patients with early breast cancer. Study Details The analysis included individual patient...
On December 15, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an FDA-approved...
Two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) highlighted new artificial intelligence (AI) tools and systems for improving distant recurrence risk stratification among patients with early-stage breast cancer. The first tested multimodal AI models with imaging, clinical,...
Using menopausal hormone therapy was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the 2025 San Antonio Breast Cancer Symposium (SABCS; Abstract GS3-01)....
A mobile health tool designed specifically for adolescent and young adult (AYA) breast cancer survivors significantly improved overall quality of life and reduced symptoms related to vaginal and arm problems when compared with usual care, according to the results of a multicenter randomized trial...
Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's risk of distant recurrence, according to an analysis presented at the 2025 San Antonio Breast Cancer...
New findings from the phase II ENHANCE clinical trial indicate that both real and sham acupuncture improve breast cancer survivors’ perceived cognitive impairment more effectively than usual care alone, while real acupuncture improves objective measures of cognitive performance better than sham...
Similar recurrence and regional recurrence-free survival rates were observed at 5 years with or without a sentinel lymph node biopsy in patients with clinically node-negative cT1-2 breast cancer treated with breast-conserving therapy, according to findings from the phase III BOOG 2013-08 trial...
Patients with hormone receptor–positive, HER2-negative advanced breast cancers had similar progression-free survival whether they were treated with sacituzumab govitecan-hziy or standard-of-care chemotherapy as the first treatment after endocrine therapy, according to results from the phase III...
The investigational oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease–free survival compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor-positive,...
Rates of local regional recurrence were very low for patients with early-stage triple-negative or HER2-positive breast cancer regardless of whether or not they received a breast MRI for staging and surgical planning, according to findings from the phase III Alliance A011104/ACRIN 6694 trial...
Adding the selective HER2 inhibitor tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III HER2CLIMB-05...
Preoperative radiation therapy added to anti–PD-1 immune checkpoint inhibition led to a significant increase in T-cell infiltration in patients with hormone receptor–positive/HER2-negative early-stage breast cancer, according to findings from the phase II P-RAD trial presented at the 2025 San...
An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a news statement issued about a study presented at the annual meeting of the Radiological Society of...
Rates of radiotherapy-associated adverse events were considerably higher with the concurrent addition of low doses of the PARP inhibitor olaparib compared with radiotherapy alone in patients with inflammatory breast cancer in the adjuvant setting, according to the results of a toxicity analysis...
Two randomized phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2025 bolster support for the use of antibody–drug conjugates—in particular, trophoblast cell surface antigen 2 (TROP2)-targeted agents—as first-line treatments for patients with triple-negative...
In an interim analysis of a Chinese phase III trial (FABULOUS) reported in The Lancet Oncology, Li et al found that the addition of the PARP inhibitor fuzuloparib to apatinib and fuzuloparib alone improved progression-free survival vs chemotherapy in patients with HER2-negative metastatic breast...
Women who undergo mammography to screen for breast cancer can be reviewed and recommended for additional lung cancer screening, thereby increasing enrollment, according to the results of a study published in the Journal of the American College of Radiology. The study, called Coordinate a Lung...
Up to 24% of breast cancers diagnosed in an 11-year period between seven outpatient facilities around New York were found in women aged 18 to 49 years, according to findings presented during the 2025 Annual Meeting of the Radiological Society of North America (RSNA; Abstract S5-SSBR02-1). “This...
An image-only artificial intelligence (AI) model demonstrated stronger and more precise risk stratification than breast density assessment for predicting 5-year risk for developing breast cancer, according to findings from a study presented at the 2025 Annual Meeting of the Radiological Society of...
A systematic review and meta-analysis published in JAMA Network Open compared the cardiotoxicity of novel antibody-drug conjugates (ADCs) with that of standard trastuzumab-containing chemotherapy in patients with HER2-positive locally advanced or metastatic breast cancer, finding that treatment...
Health-related quality-of-life analyses for proton radiation therapy and photon radiation therapy in patients with nonmetastatic breast cancer showed similar impacts on quality of life with both treatments, according to findings from the phase III RadComp consortium trial. Shannon M. MacDonald, MD, ...
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
Using an artificial intelligence (AI)–integrated workflow, DeepHealth, in computer-aided detection of breast cancer from digital breast tomosynthesis exams found 21.6% more cases than the usual standard of care, according to findings from the AI-Supported Safeguard Review Evaluation (ASSURE) study...
A large international study published by Kunkler et al in The New England Journal of Medicine examined whether chest wall radiation therapy after mastectomy improves survival for patients with early-stage breast cancer. The study, known as the SUPREMO trial, found no overall survival difference...
As reported in the The New England Journal of Medicine by Kunkler et al, the phase III SUPREMO trial showed no significant difference in 10-year overall survival in women with breast cancer receiving vs not receiving postmastectomy chest-wall irradiation. Study Details In the international trial...
The U.S. Food and Drug Administration (FDA) has approved pertuzumab-dpzb (Poherdy) as an interchangeable biosimilar to pertuzumab (Perjeta). This is the first approval of a biosimilar for pertuzumab. Pertuzumab-dpzb is a HER2/neu receptor antagonist indicated for the following: Use in combination...
Supervised aerobic and resistance exercise can improve the physical performance and strength of patients living with metastatic breast cancer, according to new data from the PREFERABLE-EFFECT study that was presented by Anne May, PhD, during the Advanced Breast Cancer Eighth International Consensus ...
As reported in The New England Journal of Medicine by Tolaney et al, interim analysis of the phase III DESTINY-Breast09 trial has shown significantly improved progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) plus pertuzumab vs a taxane (paclitaxel or docetaxel), trastuzumab,...
Almost half of all women (48%) under the age of 40 who are living with advanced breast cancer have children under the age of 18, and 64% of these young patients also experience employment disruptions after they are diagnosed, according to findings from a survey conducted by the Young Survival...
ABC Global Alliance's landmark Advanced Breast Cancer Global Decade Report 2015–2025 was recently released and published in The Breast. The report highlights significant advancements made over the past decade that have transformed care for patients with advanced breast cancer, but also reveals gaps ...
In a study reported in JAMA Oncology, Barac et al developed a risk prediction model for heart failure or cardiomyopathy (HF/CM) after breast cancer treatment. Study Details The aim of the study was to construct a model predicting the 10-year risk of developing HF/CM in women receiving systemic...
In the phase II TUXEDO-3 trial—reported in two articles in The Lancet Oncology—Fuereder et al and Bartsch et al found that the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was active in cohorts of patients with active brain metastases from advanced...
An evaluation of noncancer medications used concomitantly with cancer therapies for patients with breast cancer showed that proton pump inhibitors specifically were associated with worse survival outcomes and with an increased risk of grade 3 or higher adverse events than other classes of therapy....
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, is honoring Alan D. D'Andrea, MD, of Dana-Farber Cancer Institute, with the 2025 BRCA...
Some common hormonal contraceptives are linked to a slightly higher risk of breast cancer than others. This is shown by a new study from Uppsala University, in which researchers followed more than 2 million women and teenage girls in Sweden to identify how different hormonal contraceptives affect...
A deep learning algorithm developed for processing digital screening mammograms, Mirai, was able to detect interval breast cancers and identify women who would benefit from more frequent screenings, according to the results of a UK retrospective study published in Radiology. “If we called back 20% ...
In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Gupta et al found that the addition of carboplatin to neoadjuvant sequential taxane-anthracycline chemotherapy did not improve event-free survival, the primary endpoint, in patients with triple-negative breast...
Many immigrant women in the United States work in jobs that may expose them to chemicals linked to breast cancer, according to a recent study led by Silent Spring Institute. The analysis is among the first to examine how job-related chemical exposures may contribute to breast cancer risk among...
A major study of three of the most common cancers in women, conducted by the Cancer Survival Group at the London School of Hygiene & Tropical Medicine, found variations in the stage of disease at diagnosis, the type of treatment, and the extent to which treatment was consistent with...
Contrary to previous research, a preplanned secondary analysis of the multicenter PREVENT trial, reported by W.Gregory Hundley, MD, FACC, of Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, and colleagues in ...
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
In a retrospective analysis reported in The Lancet Oncology, Black et al examined whether linking of comprehensive whole-genome sequencing (WGS) to mortality data could add prognostic value to standard clinical data and provide a rationale for use of targeted therapies. Study Details In the...
A joint task force composed of experts from the American Society of Radiation Oncology (ASTRO), ASCO, and the Society of Surgical Oncology (SSO) has released new guidance for postmastectomy radiation therapy (PMRT) for patients with breast cancer.1 This guideline—which is intended to replace the...
Here are brief reports on three oncology approvals by the U.S. Food and Drug Administration (FDA) in September 2025: • Estrogen Receptor Antagonist in Advanced or Metastatic Breast Cancer: The FDA has approved imlunestrant (Inluriyo), an estrogen receptor antagonist, for adults with estrogen...
Patients with an aggressive type of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody-drug conjugate (ADC) sacituzumab govitecan-hziy compared with standard chemotherapy. These...
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full...
In a phase II trial (AMALEE) reported in JAMA Oncology, Cardoso et al found that a first-line ribociclib dose of 400 mg was not noninferior to a dose of 600 mg in patients with newly diagnosed hormone receptor–positive, HER2-negative advanced breast cancer. Study Details In the open-label...
Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering work on sentinel lymph node biopsy for patients with breast cancer, which has transformed the...